Mitoconix Bio

Therapeutics for Neurodegenerative Diseases

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
Mitoconix Bio
Biotechnology & Biopharmaceutical
01/01/2016
"1-10"
Go to company site

Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases.



The company’s lead drug is an inhibitor of pathological mitochondrial fragmentation and dysfunction. The drug has demonstrated in vivo efficacy in animal models of Huntington’s disease and Parkinson’s disease, and it has shown beneficial activity in patient-derived cells of Huntington’s disease, sporadic and genetic Parkinson’s disease, and sporadic and genetic Alzheimer’s disease.